Cipla Balance Sheet Health

Financial Health criteria checks 6/6

Cipla hat ein Gesamteigenkapital von ₹251.0B und eine Gesamtverschuldung von ₹6.7B, wodurch sich der Verschuldungsgrad auf 2.7% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen ₹313.8B bzw. ₹62.8B. Cipla Das EBIT des Unternehmens beträgt ₹48.1B, so dass der Zinsdeckungsgrad -86.2 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von ₹48.9B.

Key information

3.8%

Debt to equity ratio

₹9.61b

Debt

Interest coverage ratio	-90.2x
Cash	₹48.91b
Equity	₹250.95b
Total liabilities	₹62.82b
Total assets	₹313.77b

Recent financial health updates

Recent updates

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Feb 14

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Jan 26

Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely

Jan 08

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Nov 15

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Oct 05

Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?

Aug 04

Is Cipla (NSE:CIPLA) A Risky Investment?

Mar 24

A Look At The Fair Value Of Cipla Limited (NSE:CIPLA)

Mar 06

Cipla (NSE:CIPLA) Has A Pretty Healthy Balance Sheet

Dec 11

Estimating The Fair Value Of Cipla Limited (NSE:CIPLA)

Aug 19

Cipla (NSE:CIPLA) Will Pay A Dividend Of ₹5.00

Jul 30

Cipla (NSE:CIPLA) Could Easily Take On More Debt

Jul 14

If EPS Growth Is Important To You, Cipla (NSE:CIPLA) Presents An Opportunity

Jul 01

Cipla Limited (NSE:CIPLA) Shares Could Be 34% Above Their Intrinsic Value Estimate

Apr 30

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Mar 23

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Dec 18

Calculating The Fair Value Of Cipla Limited (NSE:CIPLA)

Dec 05

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Oct 27

If You Like EPS Growth Then Check Out Cipla (NSE:CIPLA) Before It's Too Late

Sep 16

Cipla Limited (NSE:CIPLA) Shares Could Be 23% Above Their Intrinsic Value Estimate

Aug 31

It's Unlikely That Cipla Limited's (NSE:CIPLA) CEO Will See A Huge Pay Rise This Year

Aug 18

Cipla (NSE:CIPLA) Could Easily Take On More Debt

Jul 12

Are Cipla Limited (NSE:CIPLA) Investors Paying Above The Intrinsic Value?

May 28

Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?

Mar 21

Here's Why I Think Cipla (NSE:CIPLA) Is An Interesting Stock

Mar 08

Do Fundamentals Have Any Role To Play In Driving Cipla Limited's (NSE:CIPLA) Stock Up Recently?

Feb 23

Have Insiders Sold Cipla Limited (NSE:CIPLA) Shares Recently?

Feb 11

Financial Position Analysis

Kurzfristige Verbindlichkeiten: CIPLADie kurzfristigen Aktiva des Unternehmens (₹184.7B) übersteigen seine kurzfristigen Passiva (₹56.5B).

Langfristige Verbindlichkeiten: CIPLADie kurzfristigen Vermögenswerte des Unternehmens (₹184.7B) übersteigen seine langfristigen Verbindlichkeiten (₹6.3B).

Debt to Equity History and Analysis

Verschuldungsgrad: CIPLA über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: CIPLA Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 30.8% auf 2.7% zurückgegangen.

Schuldendeckung: CIPLADie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (562.9%).

Zinsdeckung: CIPLA mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.

Balance Sheet

Discover healthy companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Cipla Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?

Is Cipla (NSE:CIPLA) A Risky Investment?

Cipla (NSE:CIPLA) Has A Pretty Healthy Balance Sheet

Cipla (NSE:CIPLA) Could Easily Take On More Debt

Recent updates

Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024

Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Price target increased by 8.7% to ₹1,391

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson

Third quarter 2024 earnings: EPS exceeds analyst expectations

Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Second quarter 2024 earnings released: EPS: ₹14.01 (vs ₹9.78 in 2Q 2023)

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Cipla Limited to Report Q2, 2024 Results on Oct 27, 2023

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Blackstone Reportedly Withdraws Plan to Acquire Founders' Stake in Cipla

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Cipla's Founding Family's Stake Sale Reportedly in Jeopardy over $13 Billion Valuation Target

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Blackstone Reportedly to Submit Bid for over 33% Stake in Cipla

Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?

Cipla Promoters Reportedly Mull Stake Sale to Top PE Firms Blackstone, Baring Asia

Cipla Limited Announces Change in Management

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited, Annual General Meeting, Aug 10, 2023

Cipla Limited to Report Q1, 2024 Results on Jul 26, 2023

Shibam Group Holding Limited entered into a binding term sheet to acquire additional 51% stake in Saba Investment Ltd from Cipla Limited (NSEI:CIPLA) for $6.5 million.

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited Announces Resignation of Peter Mugyenyi as Independent Director, Effective May 13, 2023

Is Cipla (NSE:CIPLA) A Risky Investment?

A Look At The Fair Value Of Cipla Limited (NSE:CIPLA)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Cipla Limited Announces the Launch of Cippoint

Cipla Limited to Report Q3, 2023 Results on Jan 25, 2023

Cipla (NSE:CIPLA) Has A Pretty Healthy Balance Sheet

Cipla Limited and Cipla Usa Inc. Announces the Launch of Leuprolide Acetate Injection Depot 22.5Mg

Price target increased to ₹1,208

Price target increased to ₹1,202

Second quarter 2023 earnings: EPS exceeds analyst expectations

Cipla Limited to Report Q2, 2023 Results on Nov 04, 2022

Cipla Limited Receives the Establishment Inspection Report Indicating Closure of the Inspection

Cipla Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Cipla Limited (NSEI:CIPLA) agreed to acquire additional 13.10% stake in Jiangsu Acebright Pharmaceutical Co. Limited for USD 16.40 million.

Estimating The Fair Value Of Cipla Limited (NSE:CIPLA)

Cipla Limited Announces Executive Changes

Upcoming dividend of ₹5.00 per share

First quarter 2023 earnings released: EPS: ₹8.51 (vs ₹8.86 in 1Q 2022)

Cipla Limited, Annual General Meeting, Aug 26, 2022

Cipla (NSE:CIPLA) Will Pay A Dividend Of ₹5.00

Cipla Limited Recommends Final Dividend for Fiscal Year 2021-22

Cipla (NSE:CIPLA) Could Easily Take On More Debt

Cipla Limited to Report Q1, 2023 Results on Jul 29, 2022

Cipla Limited Notifies That the United States Food and Drug Administration Conducted A Pre Approval Inspection

If EPS Growth Is Important To You, Cipla (NSE:CIPLA) Presents An Opportunity

Cipla Limited (NSEI:CIPLA) agreed to acquire unknown stake in GoApptiv Private Limited.

Cipla Limited (NSEI:CIPLA) entered into a definitive agreement to acquire an unknown minority stake in Achira Labs Pvt. Ltd

The South African Health Products Regulatory Authority Approves Sweet-Tasting, Heat-Stable, 4-In-1 Fixed-Dose Combination of Four Antiretroviral Treatments Developed by Cipla and DNDi

Cipla Limited Recommends Dividend for the Year 2021-22

Third quarter 2022 earnings: EPS misses analyst expectations

Consensus forecasts updated

Cipla Limited Announces Commercialisation of `RT-Direct' multiplex COVID-19 RT PCR Test kit in India

Cipla Limited (NSE:CIPLA) Shares Could Be 34% Above Their Intrinsic Value Estimate

Cipla Limited to Report Q4, 2022 Results on May 10, 2022

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Cipla Limited Announces Resignation of Kedar Upadhye from the Position of Global Chief Financial Officer

Third quarter 2022 earnings: EPS misses analyst expectations